Takeda Pharmaceutical Co. Ltd. and Nanotherapeutics Inc. have struck an agreement providing Takeda with expanded commercialization and technology rights to Nanotherapeutics' Vero cell technology, a manufacturing platform that's key to Takeda's flu vaccines and its aspirations to further develop its global vaccines business in other markets.